News & Events:AKBA

Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA cleared Marker Therapeutics Inc's  Investigational New Drug application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment. MT-601 is a multi-tumor-associated antigen-specific T cell product targeting six antigens.

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study

Akebia Therapeutics Inc (AKBA): * AKEBIA THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS. * Q2 REVENUE $126.8 MILLION. * QTRLY EARNINGS PER SHARE $0.15 Source text for Eikon: Further company coverage:

Akebia Therapeutics reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Akebia Therapeutics beat estimated earnings by 148.39%, reporting an EPS of $0.15 versus an estimate of $-0.31. Revenue was up $73.85 million from the same period last year.

Akebia Therapeutics Inc (AKBA): * AKEBIA THERAPEUTICS ANNOUNCES INITIAL FINDINGS FROM INVESTIGATOR-SPONSORED CLINICAL STUDY EVALUATING VADADUSTAT FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN SUBJECTS WITH COVID-19 AND HYPOXEMIA Source text for Eikon: Further company coverage:

Akebia to host conference call on August 4 at 4:30 p.m. ET CAMBRIDGE, Mass.

CAMBRIDGE, Mass. The trial enrolled 449 adult subjects at five hospitals who were randomized 1:1 to vadadustat 900 mg or placebo once per day orally for up to 14 days while hospitalized.

  ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

  ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

CAMBRIDGE, Mass. The options have an exercise price of $0.39 per share, which is equal to the closing price of Akebia's common stock on the grant date. About Akebia Therapeutics (AKBA) Akebia Therapeutics (AKBA), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com .

Don't forget to check out our premarket coverage here .

Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass. Akebia will host a conference call on Thursday, August 4 at 4:30 p.m. ET to discuss its financial results and provide a general business update. A replay of the conference call will be available two hours after the completion of the call through August 10, 2022.

CAMBRIDGE, Mass. The options have an exercise price of $0.35 per share, which is equal to the closing price of Akebia's common stock on the grant date. About Akebia Therapeutics (AKBA) Akebia Therapeutics (AKBA), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com .

U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. The Dow traded down 0.44% to 30,639.41 while the NASDAQ fell 0.59% to 10,936.46. The S&P also fell, dropping, 0.46% to 3,767.81. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Utilities shares rose by 1.4% on Friday.

Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. The Dow traded up 0.38% to 30,893.82 while the NASDAQ rose 0.50% to 11,084.33. The S&P also rose, gaining, 0.46% to 3,802.86. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors   Consumer discretionary shares rose by 1.7% on Friday.

Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022.

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

Don't forget to check out our premarket coverage here .